What question did this study set out to answer?

This analysis aims to evaluate the treatment tolerability of geriatric assessment-guided management compared to oncologist-guided care for older adults with advanced cancer.

July 26, 2026JCO Oncology Practice

Treatment Tolerability in Older Adults With Advanced Cancer Receiving Geriatric Assessment–Guided Versus Oncologist-Guided Primary Treatment Modification: Secondary Analysis of the GAP70+ Trial

View Full Paper

Ask AI

Bookmark

Authors

MMMostafa MohamedUniversity of Rochester DRD Q RichDepartment of Public Health JLJennifer L. LundUniversity of North Carolina at Chapel Hill

Discussion

Member takes

Implication

Randomized trial compares treatment tolerability in older adults with cancer using geriatric assessment versus oncologist guidance, indicating improved outcomes.

Key Points

This analysis aims to evaluate the treatment tolerability of geriatric assessment-guided management compared to oncologist-guided care for older adults with advanced cancer.
Secondary analysis of the GAP70+ trial (NCT02054741) involving patients age 70+ with incurable solid tumors (N=298).
Comparative assessment of treatment tolerability outcomes including grade 3 to 5 toxicity, dose reduction, and hospitalization.
Multivariable cluster-weighted generalized estimating equation models to evaluate associations.
59% experienced ≥1 grade 3 to 5 toxicity; PTM-GAM had a lower risk (RR, 0.77 [95% CI, 0.65 to 0.91]).
Secondary dose reductions occurred in 22% of patients, lower in PTM-GAM (RR, 0.47 [95% CI, 0.30 to 0.72]).
No significant reduction in ADL decline (RR, 1.04 [95% CI, 0.74 to 1.48]) and a nonsignificant reduction in unplanned hospitalization (RR, 0.69 [95% CI, 0.45 to 1.03]).

Cite This Study

Mohamed et al. (2026) studied this question.

synapsesocial.com/papers/6a65a825d3aea3239cd78932 https://doi.org/10.1200/op-25-01364

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial compares treatment tolerability in older adults with cancer using geriatric assessment versus oncologist guidance, indicating improved outcomes.

Treatment Tolerability in Older Adults With Advanced Cancer Receiving Geriatric Assessment–Guided Versus Oncologist-Guided Primary Treatment Modification: Secondary Analysis of the GAP70+ Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Treatment Tolerability in Older Adults With Advanced Cancer Receiving Geriatric Assessment–Guided Versus Oncologist-Guided Primary Treatment Modification: Secondary Analysis of the GAP70+ Trial

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider